P-536. Impact of Maternal RSV Vaccination on Hospitalization Rates in Infants Under Six Months in Buenos Aires, Argentina: A Retrospective Observational Study

Abstract Background Argentina pioneered RSV immunization in Latin America by implementing maternal RSV vaccination into its National Immunization Schedule on March 1, 2024. This program targets pregnant women between 32 and 36.6 weeks of gestation, aiming to reduce RSV-related hospitalizations and Pediatric Intensive Care Unit (PICU) admissions in infants under six months. Methods A retrospective observational study was conducted at a Buenos Aires public hospital, comparing clinical and epidemiological characteristics of infants under six months hospitalized with acute lower respiratory infections (ALRI) between 2022 and 2024. January 1st 2022 to February 29th 2024 was the pre-intervention period, while March 1st to September 30th 2024 was the post-implementation phase. Nasopharyngeal aspirates were tested for respiratory viruses. Results Ninety patients were included, 58% male (n=52), median age 4 months. Overall viral infection frequency was 90% (81), with yearly distributions of 97% (29) in 2022, 86% (37) in 2023, and 88% (15) in 2024. RSV was the most prevalent virus (36%,32), with yearly distributions of 37% (11) in 2022, 49% (21) in 2023, and 35% (6) in 2024. Of 17 infants with ALRI in 2024, eight were ineligible for maternal vaccination due to birth outside the recommended gestational window. Seven were born to vaccinated mothers, and two were not vaccinated due to programmatic errors. Among 7 infants of vaccinated mothers, one tested positive for RSV (mother vaccinated two days before premature delivery), five had other viruses, and one had no identified viral infection. On the other hand, among 6 infants with RSV infection, 5 were not vaccinated. Conclusion This preliminary analysis suggests a promising trend in RSV prevention through maternal immunization, despite the limited sample size. Timely maternal vaccination appeared protective, with RSV infection observed only in one case with suboptimal timing of vaccination due to premature delivery. Disclosures All Authors: No reported disclosures

Authors

Institutions

Publication Details

Journal
Open Forum Infectious Diseases
Published
2026-01-01
DOI
https://doi.org/10.1093/ofid/ofaf695.751
Primary Topic
Respiratory viral infections research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

P-536. Impact of Maternal RSV Vaccination on Hospitalization Rates in Infants Under Six Months in Buenos Aires, Argentina: A Retrospective Observational Study

Tomás Alconada, Martín Brizuela, Sandra Barreiro, Magali Gonzalez
Open Forum Infectious Diseases
Respiratory viral infections research
article

P-536. Impact of Maternal RSV Vaccination on Hospitalization Rates in Infants Under Six Months in Buenos Aires, Argentina: A Retrospective Observational Study

Tomás Alconada, Martín Brizuela, Sandra Barreiro, Magali Gonzalez
article en

Abstract

Abstract Background Argentina pioneered RSV immunization in Latin America by implementing maternal RSV vaccination into its National Immunization Schedule on March 1, 2024. This program targets pregnant women between 32 and 36.6 weeks of gestation, aiming to reduce RSV-related hospitalizations and Pediatric Intensive Care Unit (PICU) admissions in infants under six months. Methods A retrospective observational study was conducted at a Buenos Aires public hospital, comparing clinical and epidemiological characteristics of infants under six months hospitalized with acute lower respiratory infections (ALRI) between 2022 and 2024. January 1st 2022 to February 29th 2024 was the pre-intervention period, while March 1st to September 30th 2024 was the post-implementation phase. Nasopharyngeal aspirates were tested for respiratory viruses. Results Ninety patients were included, 58% male (n=52), median age 4 months. Overall viral infection frequency was 90% (81), with yearly distributions of 97% (29) in 2022, 86% (37) in 2023, and 88% (15) in 2024. RSV was the most prevalent virus (36%,32), with yearly distributions of 37% (11) in 2022, 49% (21) in 2023, and 35% (6) in 2024. Of 17 infants with ALRI in 2024, eight were ineligible for maternal vaccination due to birth outside the recommended gestational window. Seven were born to vaccinated mothers, and two were not vaccinated due to programmatic errors. Among 7 infants of vaccinated mothers, one tested positive for RSV (mother vaccinated two days before premature delivery), five had other viruses, and one had no identified viral infection. On the other hand, among 6 infants with RSV infection, 5 were not vaccinated. Conclusion This preliminary analysis suggests a promising trend in RSV prevention through maternal immunization, despite the limited sample size. Timely maternal vaccination appeared protective, with RSV infection observed only in one case with suboptimal timing of vaccination due to premature delivery. Disclosures All Authors: No reported disclosures

Open Forum Infectious DiseasesVol. 13(Supplement_1)
Universidad Autónoma de la Ciudad de México (MX), El Hospital General de Agudos Carlos G. Durand (AR)
Good health and well-being
Openalex Percentile: Top 92%
Respiratory viral infections research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.